ACTIMIS is a multinational, multicenter, randomized, double-blind, placebo-controlled, single-parallel, escalating dose phase 1b/2a safety and efficacy study of glenzocimab used as an add-on to standard of care therapy for acute ischemic stroke.
GARDEN is a randomized, double blind, multicenter, placebo-controlled, parallel group, exploratory efficacy and safety phase 2 study of glenzocimab in sars-cov-2-related acute respiratory distress syndrome (ARDS).
ACTISAVE is a randomized, double-blind, multicenter, multinational, placebo-controlled, parallel group, single dose, phase 2/3 adaptive efficacy and safety study of glenzocimab used as an add-on therapy on top of standard of care in the 4.5 hours following an acute ischemic stroke.
GREEN is a randomized, double-blind, multicenter, placebo-controlled, efficacy and safety phase 2/3 study of glenzocimab used as an add-on therapy on top of mechanical thrombectomy for acute ischemic stroke. The GREEN study is sponsored by Paris Public Hospitals (Assistance Publique – Hôpitaux de Paris) and is part of the RHU BOOSTER, receiving financial support from the French National Research Agency (Agence Nationale de la Recherche) and the Government’s Investments for the Future program (Programme Investissements d’Avenir).
LIBERATE is a phase II, randomised, double-bLInd, placeBo-controllEd tRiAl To invEstigate the efficacy and safety of glenzocimab and the mechanism of inhibiting platelet GPVI as a treatment for ST-elevation myocardial infarction (STEMI). The LIBERATE study is sponsored by the Queen Elizabeth Hospital, Birmingham (UK). The study is receiving financial support from Acticor.
The GALICE trial is a phase 2/3, randomized, double-blind, placebo controlled, multicentric trial to evaluate the efficacy of glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy. The study is sponsored by the Rothschild foundation hospital and is receiving financial support by the National Clinical Research Hospital Program of the French Ministry of Health (PHRC).